Clinical spectrum and genotype-phenotype correlations in PRRT2 Italian patients
Prrt2 is a neuron-specific protein expressed at axonal and pre-synaptic domains, involved in synaptic neurotransmitter release and modulation of intrinsic excitability. Mutations in PRRT2 cause a spectrum of autosomal dominant paroxysmal neurological disorders including epilepsy, movement disorders,...
Gespeichert in:
Veröffentlicht in: | European journal of paediatric neurology 2020-09, Vol.28, p.193-197 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Prrt2 is a neuron-specific protein expressed at axonal and pre-synaptic domains, involved in synaptic neurotransmitter release and modulation of intrinsic excitability. Mutations in PRRT2 cause a spectrum of autosomal dominant paroxysmal neurological disorders including epilepsy, movement disorders, and hemiplegic migraine and show incomplete penetrance and variable expressivity.
We assessed the diagnostic rate of PRRT2 in a cohort of Italian patients with epilepsy and/or paroxysmal kinesigenic dyskinesia (PKD) and evaluated genotype-phenotype correlations. Clinical data were collected using a structured questionnaire.
Twenty-seven out of 55 (49.1%) probands carried PRRT2 heterozygous pathogenic variants, including six previously known genotypes and one novel missense mutation. A family history of epilepsy starting in the first year of life and/or PKD was strongly suggestive of a PRRT2 pathogenic variant. Epilepsy patients harbouring PRRT2 pathogenic variants showed earlier seizure onset and more frequent clusters compared with PRRT2-negative individuals with epilepsy. Moreover, we did also identify individuals with PRRT2 pathogenic variants with atypical age at onset, i.e. childhood-onset epilepsy and infantile-onset PKD. However, the lack of a clear correlation between specific PRRT2 genotypes and clinical manifestations and the high incidence of asymptomatic carriers suggest the involvement of additional factors in modulating expressivity of PRRT2-related disorders. Finally, our study supports the pleiotropic and multifaceted physiological role of PRRT2 gene which is emerging from experimental neuroscience.
PRRT2-associated paroxysmal disorders have a quite definite age at onset: 3–12 months for epilepsy, first decade for paroxysmal kinesigenic dyskinesia (PKD) and hemiplegic migraine. Atypical presentations (in red) can occur childhood-onset epilepsy and infantile- or adult-onset PKD. A novel missense variant c.809T>A (p.Ile270Asn) causes PKD. [Display omitted]
•The diagnostic rate and genotype-phenotype correlation for PRRT2 were assessed in Italian patients with epilepsy or PKD.•PRRT2 pathogenic variants were more associated with onset in the first year of life and a family history of epilepsy or PKD.•Carriers of PRRT2 pathogenic variants displayed earlier seizure onset and more frequent seizure clusters.•Incomplete penetrance and the lack of genotype-phenotype correlation suggest a complex modulation in expressivity of PRRT2. |
---|---|
ISSN: | 1090-3798 1532-2130 |
DOI: | 10.1016/j.ejpn.2020.06.005 |